Viewpoint: Why the FDA’s decision to overrule its evaluatory panel and approve dementia-relief drug Aduhelm was a mistake

Viewpoint: Why the FDA’s decision to overrule its evaluatory panel and approve dementia-relief drug Aduhelm was a mistake

STAT | 
Like many people, I was shocked when the Food and Drug Administration ignored the advice of its neurological drugs advisory ...
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists